Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor

AKTAŞ Y., ANDRİEUX K., ALONSO M. J., CALVO P., Gursoy R. N., COUVREUR P., ...Daha Fazla

INTERNATIONAL JOURNAL OF PHARMACEUTICS, cilt.298, sa.2, ss.378-383, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 298 Sayı: 2
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1016/j.ijpharm.2005.03.027
  • Dergi Adı: INTERNATIONAL JOURNAL OF PHARMACEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.378-383
  • Anahtar Kelimeler: chitosan, nanoparticles, Z-DEVD-FMK, HPLC, PEGYLATED POLYCYANOACRYLATE NANOPARTICLES, BRAIN, DELIVERY, CARRIERS
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

The aim of this work was to develop a formulation for Z-DEVD-FMK, a peptide which is a caspase inhibitor and has been used in experimental animal studies for a decade. Peptide loaded chitosan nanoparticles were obtained by ionotropic gelation process and Z-DEVD-FMK was quantified by an HPLC method. The influence of the initial peptide concentration on the nanoparticle characteristics and release behavior was evaluated. The CS nanoparticles have a particle diameter (Z-average) ranging from approximately 313-412 nm and a positive zeta potential (20-28 mV). The formulation with the initial peptide concentration of 400 ng/ml provided the highest loading capacity (0.46%) and the highest extent of release (65% at 24 h) suggesting the possibility to achieve a therapeutic dose. According to the data obtained, this chitosan-based nanotechnology opens new and interesting perspectives for anticaspase activity. (c) 2005 Elsevier B.V. All rights reserved.